nach oben

Current Neurology and Neuroscience Reports

Erschienen in:

01.04.2011

Paraneoplastic Neurologic Disorders in Children

verfasst von: Elizabeth M. Wells, Josep Dalmau

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Paraneoplastic neurologic syndromes are rare disorders that have potentially devastating effects on the developing brain. Recently, there has been increased interest in possible immunotherapy for these disorders. Recognition of paraneoplastic syndromes in children may lead to early detection and treatment of the pediatric cancer and may diminish the neurologic damage that is the major source of morbidity in children with successfully treated tumors. This article reviews the presenting symptoms, immunology, long-term sequelae, and management options for paraneoplastic neurologic syndromes, focusing on those most commonly reported in children: opsoclonus-myoclonus ataxia, limbic encephalitis, and anti-NMDAR encephalitis. The child neurologist plays an important role in recognizing these disorders, initiating a tumor search, and directing ongoing treatment and management of neurologic symptoms after oncologic treatment is complete. Given the rarity of these conditions, multisite collaborative efforts are needed to develop standardized approaches to characterization and treatment.

•• Dalmau J, Rosenfeld MR: Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008 Apr;7(4):327–40. This article reviews classic concepts about paraneoplastic neurologic disorders and recent clinical and immunologic developments.PubMedCrossRef

Posner JB: Paraneoplastic opsoclonus/myoclonus: B cells, T cells, both, or neither? Neurology. 2004 May 11;62(9):1466–7.PubMed

Sommer C, Weishaupt A, Brinkhoff J, et al.: Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet. 2005 Apr 16–22;365(9468):1406–11.PubMedCrossRef

Graus F, Delattre JY, Antoine JC, et al.: Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1135–40.PubMedCrossRef

Turkel SB, Brumm VL, Mitchell WG, et al.: Mood and behavioral dysfunction with opsoclonus-myoclonus ataxia. J Neuropsychiatry Clin Neurosci. 2006 Spring;18(2):239–41.PubMed

Pang KK, de Sousa C, Lang B, et al.: A prospective study of the presentation and management of dancing eye syndrome/opsoclonus-myoclonussyndrome in the United Kingdom. Eur J Paediatr Neurol. 2010 Mar;14(2):156–61. Epub 2009 May 6.PubMedCrossRef

Pohl KR, Pritchard J, Wilson J: Neurological sequelae of the dancing eye syndrome. Eur J Pediatr. 1996 Mar;155(3):237–44.PubMedCrossRef

Younes-Mhenni S, Janier MF, Cinotti L, et al.: FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain. 2004 Oct;127(Pt 10):2331–8. Epub 2004 Sep 10PubMedCrossRef

Linke R, Schroeder M, Helmberger T, Voltz R: Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology. 2004 Jul 27;63(2):282–6.PubMed

10.

Titulaer MJ, Soffietti R, Dalmau J, et al.: Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force. Eur J Neurol. 2010 Sep 29.

11.

Kushner BH, Kramer K, Modak S, et al.: Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma. J Clin Oncol. 2009 Mar 1;27(7):1041–6. Epub 2009 Jan 26.PubMedCrossRef

12.

McGarvey CK, Applegate K, Lee ND, Sokol DK: False-positive metaiodobenzylguanidine scan for neuroblastoma in a child with opsoclonus-myoclonus syndrome treated with adrenocorticotropic hormone (ACTH). J Child Neurol. 2006 Jul;21(7):606–10.PubMedCrossRef

13.

Swart JF, de Kraker J, van der Lely N: Metaiodobenzylguanidine total-body scintigraphy required for revealing occult neuroblastoma in opsoclonus-myoclonus syndrome. Eur J Pediatr. 2002 May;161(5):255–8. Epub 2002 Mar 13.PubMedCrossRef

14.

Blaes F, Pike MG, Lang B: Autoantibodies in childhood opsoclonus-myoclonus syndrome. J Neuroimmunol. 2008 Sep 15;201–202:221–6. Epub 2008 Aug 6.PubMedCrossRef

15.

van Vuurden DG, Plötz FB, de Jong M, et al.: Therapeutic total plasma exchange in a child with neuroblastoma-related anti-Hu syndrome. Pediatr Nephrol. 2005 Nov;20(11):1655–6. Epub 2005 Aug 24.PubMedCrossRef

16.

Tate ED, Allison TJ, Pranzatelli MR, et al.: Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome. J Pediatr Oncol Nurs. 2005 Jan–Feb;22(1):8–19.PubMedCrossRef

17.

Raffaghello L, Conte M, De Grandis E, Pistoia V: Immunological mechanisms in opsoclonus–myoclonus associated neuroblastoma. European Journal of Paediatric Neurology 2009;13(3):219–23.PubMedCrossRef

18.

Fühlhuber V, Bick S, Kirsten A, et al.: Elevated B-cell activating factor BAFF, but not APRIL, correlates with CSF cerebellar autoantibodies in pediatric opsoclonus-myoclonus syndrome. J Neuroimmunol. 2009 May 29;210(1–2):87–91. Epub 2009 Mar 31.PubMedCrossRef

19.

Pranzatelli MR, Tate ED, Hoefgen ER, et al.: Therapeutic down-regulation of central and peripheral B-cell-activating factor (BAFF) production in pediatric opsoclonus-myoclonus syndrome. Cytokine. 2008 Oct;44(1):26–32. Epub 2008 Aug 9.PubMedCrossRef

20.

Krasenbrink I, Fühlhuber V, Juhasz-Boess I, et al.: Increased prevalence of autoimmune disorders and autoantibodies in parents of children with opsoclonus-myoclonus syndrome (OMS). Neuropediatrics. 2007 Jun;38(3):114–6.PubMedCrossRef

21.

Kirsten A, Beck S, Fühlhuber V, et al.: New autoantibodies in pediatric opsoclonus myoclonus syndrome. Ann N Y Acad Sci. 2007 Sep;1110:256–60PubMedCrossRef

22.

Sabater L, Xifró X, Saiz A, et al.: Analysis of antibodies to neuronal surface antigens in adult opsoclonus-myoclonus. J Neuroimmunol 2008;196:188–91PubMedCrossRef

23.

Ertle F, Behnisch W, Al Mulla NA, et al.: Treatment of neuroblastoma-related opsoclonus-myoclonus-ataxia syndrome with high-dose dexamethasone pulses. Pediatr Blood Cancer. 2008 Mar;50(3):683–7.PubMedCrossRef

24.

• Pranzatelli MR, Tate ED, Swan JA, et al.: B cell depletion therapy for new-onset opsoclonus-myoclonus. Mov Disord. 2010 Jan 30;25(2):238–42. Authors report that the combination of rituximab with conventional agents as initial therapy was effective and safe in 12 patients.PubMedCrossRef

25.

De Grandis E, Parodi S, Conte M, et al.: Long-term follow-up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome. Neuropediatrics. 2009 Jun;40(3):103–11. Epub 2009 Dec 17.PubMedCrossRef

26.

Pranzatelli MR, Tate ED, Dukart WS, et al.: Sleep disturbance and rage attacks in opsoclonus-myoclonus syndrome: response to trazodone. J Pediatr. 2005 Sep;147(3):372–8.PubMedCrossRef

27.

Koh PS, Raffensperger JG, Berry S, et al.: Long-term outcome in children with opsoclonus-myoclonus and ataxia and coincident neuroblastoma. J Pediatr. 1994 Nov;125(5 Pt 1):712–6.PubMed

28.

Schmahmann JD: Neuropsychol Rev. 2010 Sep;20(3):236–60. Epub 2010 Sep 7.

29.

Wells EM, Walsh KS, Khademian ZP, et al.: The cerebellar mutism syndrome and its relation to cerebellar cognitive function and the cerebellar cognitive affective disorder. Dev Disabil Res Rev. 2008;14(3):221–8.PubMedCrossRef

30.

Haberlandt E, Bast T, Ebner A, et al.: Limbic encephalitis in children and adolescents. Arch Dis Child. 2010 Oct 19.

31.

Yeung WL, Li CK, Nelson EA, et al.: Unusual neurological presentation of neuroblastoma. Hong Kong Med J. 2003 Apr;9(2):142–4.PubMed

32.

Gultekin SH, Rosenfeld MR, Voltz R, et al.: Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain. 2000 Jul;123 (Pt 7):1481–94.PubMedCrossRef

33.

Vedeler CA, Antoine JC, Giometto B, et al.: Paraneoplastic Neurological Syndrome Euronetwork. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol. 2006 Jul;13(7):682–90PubMedCrossRef

34.

Graus F, Cordon-Cardo C, Posner J: Neuronal antinuclear antibodyin sensory neuronopathy from lung cancer. Neurology 1985;35:538–543.PubMed

35.

Graus F, Elkon KB, Cordon-Cardo C, et al.: Sensory neuronopathy and small cell lung cancer; antineuronal antibody that also reacts with the tumor. Am J Med 1986;80:45–52.PubMedCrossRef

36.

Dalmau J, Graus F, Rosenblum MK, et al.: Anti-Hu associated paraneoplastic encephalomyelitis/sensory neuropathy: a clinical study of 71 patients. Medicine (Baltimore) 1992, 71(2):59–72.

37.

Darnell RB: NMDA receptor as a target in paraneoplastic encephalitis. Ann Neurol. 2007 Jan;61(1):3–4.PubMedCrossRef

38.

• Dalmau J, Tüzün E, Wu H-Y, et al.: Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007;61:25–36. This is the first report of the identification of antibodies against NR1/2 heteromers of the NMDAR.

39.

•• Dalmau J, Gleichman AJ, Hughes EG, et al.: Anti-NMDA receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091–1098. Based in a study of 100 patients, this article reports the syndrome and immunological findings that characterize anti-NMDAR encephalitis.

40.

•• Florance NR, Davis RL, Lam C, et al.: Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. 2009 Jul;66(1):11–8. This article characterizes a large sample of children with this relatively newly discovered condition that is increasingly recognized in children.

41.

Hughes EG, Peng X, Gleichman AJ, et al.: Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci. 2010 Apr 28;30(17):5866–75.PubMedCrossRef

42.

• Lebas A, Husson B, Didelot A, et al.: Expanding spectrum of encephalitis with NMDA receptor antibodies in young children.J Child Neurol. 2010 Jun;25(6):742–5. Epub 2009 Oct 15. This article presents young cases of paraneoplastic encephalitis with NMDA antibodies including the first known case associated with neuroblastoma.PubMedCrossRef

43.

Lesher AP, Myers TJ, Tecklenburg F, et al.: Anti-N-methyl-D-aspartate receptor encephalitis associated with an ovarian teratoma in an adolescent female. J Pediatr Surg. 2010 Jul;45(7):1550–3.PubMedCrossRef

44.

Sonn TS, Merritt DF: Anti-NMDA-receptor encephalitis: an adolescent with an ovarian teratoma. J Pediatr Adolesc Gynecol. 2010 Oct;23(5):e141–4.PubMedCrossRef

45.

Sillevis-Smitt P, Grefkens J, de Leeuw B, et al.: Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol 2002;249:745–753.

46.

Shams’ili S, de Beukelaar J, Gratama JW, et al.: An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol. 2006 Jan;253(1):16–20.PubMedCrossRef

47.

Iizuka T, Yoshii S, Kan S, et al.: Reversible brain atrophy in anti-NMDA receptor encephalitis: a long-term observational study. J Neurol. 2010 Oct;257(10):1686–91. Epub 2010 Jun 2.PubMedCrossRef

48.

Drukker CA, Heij HA, Wijnaendts LC, et al.: Paraneoplastic gastro-intestinal anti-Hu syndrome in neuroblastoma. Pediatr Blood Cancer. 2009 Mar;52(3):396–8.PubMedCrossRef

49.

Emir S, Kutluk MT, Göğüş S, et al.: Paraneoplastic cerebellar degeneration and Horner syndrome: association of two uncommon findings in a child with Hodgkin disease. J Pediatr Hematol Oncol. 2000 Mar–Apr;22(2):158–61.PubMedCrossRef

50.

de Buys Roessingh AS, Loriot MH, Wiesenauer C, et al.: Lambert-Eaton myasthenic syndrome revealing an abdominal neuroblastoma. Pediatr Surg. 2009 Aug;44(8):E5–7.CrossRef

51.

Ghosh JB, Roy M, Peters T: Thymoma associated with myasthenia gravis in infancy. Indian J Pediatr. 2009 Oct;76(10):1057–8. Epub 2009 Nov 12.PubMedCrossRef

52.

Morris P, Dare J: Juvenile dermatomyositis as a paraneoplastic phenomenon: an update. J Pediatr Hematol Oncol. 2010 Apr;32(3):189–91.PubMedCrossRef

Titel: Paraneoplastic Neurologic Disorders in Children
verfasst von: Elizabeth M. Wells
Josep Dalmau
Publikationsdatum: 01.04.2011
Verlag: Current Science Inc.
Erschienen in: Current Neurology and Neuroscience Reports / Ausgabe 2/2011
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-010-0169-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2011

The Sleep Manifestations of Frontal Lobe Epilepsy

Hormonal Manipulation Strategies in the Management of Menstrual Migraine and Other Hormonally Related Headaches

Furthering the Understanding of the Pathophysiology of Narcolepsy

Molecular Genetics of Neuronal Migration Disorders

Risk Stratification of Medulloblastoma: A Paradigm for Future Childhood Brain Tumor Management Strategies